More stories

  • in

    JPMorgan pledges $2.5 trillion over the next decade toward climate change

    In this articleJPMPedestrians walk in front of the JPMorgan Chase headquarters building in New York.Scott Mlyn | CNBCJPMorgan Chase said Thursday it will commit more than $2.5 trillion over the next decade toward long-term solutions that tackle climate action and contribute to sustainable development.Within the initiative, $1 trillion is earmarked for green projects, including renewable energy and clean technologies that are focused on speeding the transition to a low-carbon economy.The $2.5 trillion target, which begins this year and runs through the end of 2030, will also finance and facilitate transactions that support socioeconomic progress in developing countries, as well as economic inclusion in developed markets.The latter effort will focus on small business financing, home lending and affordable housing, education and health care. Included within this category is the $30 billion JPMorgan committed last October to closing the racial wealth gap in the U.S.”Climate change and inequality are two of the critical issues of our time, and these new efforts will help create sustainable economic development that leads to a greener planet and critical investments in underserved communities,” CEO Jamie Dimon said.”Business, government and policy leaders must work together to support long-term solutions that advance economic inclusion, bolster sustainable development and further the transition to a low-carbon economy. We are committed to doing our part,” he said.Thursday’s announcement comes after JPMorgan said last fall it will establish emission targets for its financing portfolio. The firm said targets would be set on a sector-by-sector basis, and will first focus on the oil and gas, electric power, and automotive manufacturing sectors.The targets, which the firm said it would begin setting in 2021, will be within the parameters outlined by the 2015 Paris Agreement.Dimon also addressed the enormous opportunity created by the energy transition in his 2020 annual letter to shareholders.”There’s huge opportunity in sustainable and low-carbon technologies and businesses,” he said.”While many of these technologies and companies are mature, many more are just getting started—and more will need to be created in the coming decades. In addition, all companies will need capital and advice to help them innovate, evolve and become more efficient while staying competitive in a changing world,” Dimon said in the letter.The bank facilitated in 2020 more than $220 billion in transactions related to sustainable development, more than $55 billion of which was for green initiatives. The total exceeded the firm’s initial $200 billion target for the year.Some believe the bank has not done enough.A recent report from a collection of climate organizations found that between 2016 — the first full year after the Paris Agreement was signed — and 2020, JPMorgan’s total fossil fuel financing hit $317 billion. That’s more than any of the major banks.Citi and Wells Fargo were the second- and third-largest financers at $237 billion and $223 billion, respectively.While JPMorgan still tops the list, the bank — which is the largest by assets under management in the U.S. — has decreased its lending since the Paris Agreement was signed, according to the report.A representative from the firm previously said that the bank does not comment on third-party reports.— CNBC’s Hugh Son contributed reporting.Enjoyed this article?For exclusive stock picks, investment ideas and CNBC global livestreamSign up for CNBC ProStart your free trial now More

  • in

    Bank of America tops estimates on Wall Street trading and banking, release of loan-loss reserves

    In this articleBACBrian Moynihan, CEO, Bank of AmericaScott Mlyn | CNBCBank of America reported Thursday profit that topped Wall Street estimates on booming investment banking and trading results, as well as the release of loan-loss reserves as fewer consumers were expected to default on debts.The bank posted first-quarter profit of $8.1 billion, or 86 cents a share, exceeding the 66 cents a share expected by analysts surveyed by Refinitiv. The company produced $22.9 billion in revenue, edging out the $22.1 billion estimate.Bank of America separately announced a $25 billion stock repurchase program; the stock gained 1.2% in early trading.”While low interest rates continued to challenge revenue, credit costs improved and we believe that progress in the health crisis and the economy point to an accelerating recovery,” CEO Brian Moynihan said in the release.Like other banking rivals, Bank of America saw a large benefit from the improving U.S. economic outlook in recent months: It released $2.7 billion in reserves for loan losses in the quarter. Last year, the firm set aside $11.3 billion for credit losses, when the industry believed that a wave of defaults tied to the coronavirus pandemic was coming.Instead, government stimulus programs appear to have prevented most of the feared losses, and banks have begun to release more of their reserves this quarter.Like JPMorgan and Goldman, the bank also saw a boost from its trading operations. Fixed income trading revenue jumped 22% to $3.3 billion, exceeding analysts’ estimate by roughly $660 million. Equities revenue rose 10% to $1.8 billion, about $170 million more than expected.The firm’s Wall Street bankers were busy as well: The firm posted a 62% increase in investment banking fees to $2.2 billion, almost $400 million more than analysts had expected, fueled by a 218% surge in equity underwriting fees to $900 million.On Wednesday, JPMorgan Chase and Wells Fargo each posted results that exceeded analysts’ expectations on reserve releases, while Goldman Sachs beat estimates on strong advisory and trading results.Shares of Bank of America have climbed 32% this year, exceeding the 26% gain of the KBW Bank Index.Here are the numbers:Earnings: 86 cents a share, vs. 66 cents a share expected by analysts polled by Refinitiv.Revenue: $22.9 billion, vs. $22.1 billion expected.This story is developing. Please check back for updates.Enjoyed this article?For exclusive stock picks, investment ideas and CNBC global livestreamSign up for CNBC ProStart your free trial now More

  • in

    Market is 'completely ignoring' serious risks associated with U.S.-China relations, Asia expert Stephen Roach warns

    There’s a significant risk catching economist Stephen Roach’s attention, and it has nothing to do with earnings season.Roach, one of the world’s leading authorities on Asia, is concerned U.S.-China relations could erode further in the coming weeks.”There are a lot of balls in the air right now that are very worrisome,” the former Morgan Stanley Asia chairman told CNBC’s “Trading Nation” on Wednesday. “You’ve got a real problem here, and it’s one that worries me a lot, and I think the markets are completely ignoring.”Roach sees bipartisan in the Senate for the Strategic Competition Act of 2021 as a troubling development. His reason: it reflects a hard-line approach against China that could spark retaliation.”My fear for the last several years is that what started out as trade war would turn into a tech war, and then eventually morph into a cold war,” Roach said. “Those fears have come to pass. Just this week, there are significant developments that lead me to underscore that risk.”He also lists a new U.S. intelligence report as particularly worrisome.’The annual threat assessment was released yesterday [Tuesday] by the office of national intelligence and it clearly labeled China as America’s No. 1 threat,” said Roach, who’s monitoring building tensions between China and Japan, too.According to Roach, it appears President Joe Biden will continue many of the Trump administration’s policies against China.Roach warns the increased U.S.-China tensions exacerbate his dollar crash call. Late last spring, he predicted the greenback would drop 35% against other major currencies over the next year or two.”The dollar moved down sharply in the second half of 2020. It reversed course in the first quarter of this year and now it’s under downward pressure again,” Roach said. “It reflects my concerns over the current account deficit in the United States, unwillingness of the Fed to tighten interest rates for the conceivable future, and then the possibility that Europe may end up having a stronger commitment to fiscal policy than any of us, myself included, thought.”He’s also concerned the current backdrop with China could exacerbate the danger.”You add to that pressures on America’s role as a global leader that may be brought into play by frictions with China and there’s still, in my view, considerable downside left for the U.S. dollar,” Roach said.The U.S. Dollar Currency Index is off almost 1% over the past week. It’s down more than 7% over the past year.Disclaimer More

  • in

    Merck ends development of Covid drug it acquired from OncoImmune

    Merck announced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19 after the Food and Drug Administration asked the company to provide additional data to support an emergency use authorization.New Jersey-based Merck acquired the drug, MK-7110, through its $425 million acquisition of privately held biopharmaceutical company OncoImmune late last year.An interim analysis of clinical trial data suggested the drug improved the chances of recovery for the sickest patients with Covid-19 and reduced the risk of death or respiratory failure.However, Merck disclosed in February that U.S. regulators had asked for more data on the drug beyond the phase three trial already conducted. At the time, the company said it no longer expected to supply the U.S. with the drug in the first half of 2021.Now, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.”Based on the additional research that would be required – new clinical trials as well as research related to manufacturing at scale – MK-7110 would not be expected to become available until the first half of 2022,” the company said in a press release.The announcement marks another disappointment for Merck in efforts to combat the pandemic.In January, it announced it would end the development of its two Covid-19 vaccines. In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from Covid-19 as well as those reported for other vaccines, according to the company.While Merck is discontinuing MK-7110, the company said it will move forward with its oral antiviral drug, molnupiravir, in a phase three clinical trial testing non-hospitalized patients with Covid-19.”We continue to make progress in the clinical development of our antiviral candidate molnupiravir,” Roy Baynes, Merck’s chief medical officer, said in a release. “Data from the dose-finding portion of these studies are consistent with the mechanism of action and provide meaningful evidence for the antiviral potential of the 800 mg dose.”–Reuters contributed to this report. More

  • in

    PepsiCo revenue rises 6.8% despite unbalanced economic recovery outside of the U.S.

    In this articlePEPOPHICases of Pepsi are shown for sale at a store in Carlsbad, California, April 22, 2017.Mike Blake | ReutersPepsiCo on Thursday reported quarterly earnings that topped analyst estimates even as the company saw uneven recoveries in its international markets.It’s the company’s first quarter facing tough comparisons to early stockpiling. CEO Ramon Laguarta said that the company also dealt with weather-related business interruptions in the United States.Shares of the company rose less than 1% in premarket trading.Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by Refinitiv:Earnings per share: $1.21 adjusted vs. $1.12 expectedRevenue: $14.82 billion vs. $14.55 billion expectedPepsi reported fiscal first-quarter net income of $1.71 billion, or $1.24 per share, up from $1.34 billion, or 96 cents per share, a year earlier.Excluding items, the food and beverage giant earned $1.21 per share, beating the $1.12 per share expected by analysts surveyed by Refinitiv.Net sales rose 6.8% to $14.82 billion, topping expectations of $14.55 billion. Organic revenue, which strips out the impact of foreign currency, acquisitions and divestitures, grew by 2.4% in the quarter as consumers maintained their pandemic snacking habits.Frito-Lay North America’s organic revenue jumped 3%. New products like Doritos 3D Crunch and Cheetos Crunch Pop Mix encouraged consumers to keep snacking. The segment’s profits, however, were hurt by February’s winter storms.The North American beverage business reported organic revenue growth of 2%. The company saw double-digit revenue growth for its Bubly sparkling water and Starbucks ready-to-drink coffees.Quaker Foods North America’s organic revenue rose just 1% in the quarter. The segment has benefited the most from the at-home breakfast trend, which could disappear as more consumers return to their offices.Outside of North America, results were mixed as some markets grappled with new virus outbreaks. Most of its international markets’ first quarter includes only January and February. Europe’s organic revenue was unchanged from the year prior, while Africa, Middle East and South Asia’s slipped 1%. Latin America’s organic revenue rose 3%, but the Asia Pacific, Australia and New Zealand and China Region segment reported climbed a whopping 18%.The company reiterated its 2021 forecast, which expects mid-single digit organic revenue growth and high-single digit constant currency earnings per share. Pepsi is predicting strong sales from its North American beverages unit as more consumers visit restaurants and movie theaters, but demand for Quaker Foods products will likely moderate. More

  • in

    Shake Shack has 'big plans for Asia' as it ramps up expansion in the region

    In this articleSHAKNew York burger chain Shake Shack has “big plans for Asia,” its CEO has said, as the company embarks on a regional expansion drive.South China and Macao will be first in line for new outlets — with locations in Shenzhen, Guangzhou and Macao’s casino resort The Londoner set to open in the coming months, Randy Garutti told CNBC Thursday.Singapore and Beijing are preparing for new openings too, according to the company’s website.Our business has been incredibly resilient in Asia.Randy GaruttiCEO, Shake ShackThe CEO said the rollout responds to strong demand over the past year, and will cement Asia as “one of the most important positions” in the company.”Our business has been incredibly resilient in Asia,” Garutti told “Street Signs.””We’ve opened in Shanghai. Even last year, through the pandemic, in August we opened in Beijing. We’ve got our sights now on Macao and in the south, starting in Shenzhen.”Overall, the business plans to open 35 to 40 new locations globally in fiscal 2021. In 2022, it will add a further 45 to 50 openings. Garutti did not say how many of those would be within Asia.An order of fast food meal (hamburger, chips and soft drink) at a Shake Shack restaurant at Sanitun on August 13, 2020 in Beijing, China.VCG | Visual China Group | Getty ImagesAlready, Shake Shack has at least 48 locations in Asia, including Japan, South Korea and the Philippines.Garutti said the brand will continue to partner with Hong Kong’s Maxim’s Caterers to facilitate its rollout in Greater China.He insisted customers would still enjoy Shake Shack’s classic taste, though he added that some new locations would also feature specialty shakes, for instance in Shenzhen and Macao, as well as localized artwork.”People want us to be Shake Shack from New York,” said Garutti. “They don’t want us to change the menu. But what we find ways to do is have these little cameos.” More

  • in

    India's second wave of Covid shows no signs of slowing as country reports over 200,000 new cases

    A man gets vaccinated at the Urban Primary Health Center in Uttar Pradesh, India.Pradeep Gaur | SOPA Images | LightRocket | Getty ImagesIndia’s second wave of coronavirus infection shows no signs of slowing down.The South Asian country reported more than 200,000 new cases and more than 1,000 deaths over a 24-hour period on Thursday, according to health ministry data. Most of the new infections are being reported in a handful of states, including the western state of Maharashtra, which is home to India’s financial capital Mumbai.Government data also suggests that more states are showing an upward trajectory in reported cases, which have been rising since February. The death rate is also increasing as hospitals face pressure over supplies, including the number of beds available. For example, a doctor’s association in the state of Gujarat has reportedly asked the government to ensure 100% oxygen supply for hospitals treating Covid-19 patients.India still has a relatively high recovery rate.Since the beginning of April, India has reported more than 1.9 million new cases and over 10,600 deaths, per CNBC’s calculations of health ministry data. Between April 1 and April 7, India reported more than 652,000 cases. That number has nearly doubled in the eight days since.Earlier this week, India overtook Brazil to become the second worst-infected country behind the United States, just months after Prime Minister Narendra Modi reportedly declared victory over Covid-19.Maharashtra lockdownOn Wednesday evening, India’s richest state went into a lockdown set to last until May 1 to break the chain of transmission. Maharashtra is considered the epicenter of India’s second wave of infections.Guidelines issued by Maharashtra’s chief minister said only essential services — including public transport and grocery — would be operational between 7 a.m. and 8 p.m. local time and people would not be allowed in public spaces without valid reasons.The central government has reportedly blamed the second wave on people’s lack of commitment toward wearing masks and practicing safe distancing.In recent weeks, politicians held election rallies in states like West Bengal where large crowds gathered — most of them without wearing masks. There were also a string of religious gatherings that took place in various parts of the country where thousands gathered in close proximity.There is also growing concern about the double mutation of a Covid-19 variant that was discovered in India, which could make the virus more contagious and better at evading the body’s defenses.India’s vaccination driveIndia’s health ministry data as of Wednesday showed more than 110 million doses of vaccines have been administered since the government began an ambitious inoculation program in January.Some states, including Maharashtra, are reportedly facing severe vaccine shortages that is halting their inoculation drives. The Indian government, in response, has accused those states of diverting attention away from their failure to control the virus — it maintains that the issue is over planning instead of a supply shortage.But the Serum Institute of India, which is manufacturing AstraZeneca’s shot, known locally as Covishield, has said its production capacity is “very stressed.”This week India approved a third vaccine for emergency use — Russia-developed Sputnik V. More

  • in

    China could be one step closer to scrapping its controversial childbirth limits

    People walk past the headquarters of the People’s Bank of China (PBOC), the central bank, in Beijing, China September 28, 2018. Jason Lee | ReutersBEIJING — China may be one step nearer to abandoning its controversial policy of restricting childbirth.The central bank released a paper late Wednesday suggesting the country remove limits on how many children people can have, suggesting that China should “fully liberalize and encourage childbirth.”As China’s population began aging, Chinese authorities began several years ago to roll back the decades-old “one-child policy” and allow people to have two children. But births continued to fall, dropping 15% in 2020 in a fourth-straight year of decline.”In order to achieve the long-term goals in 2035, China should fully liberalize and encourage childbirth, and sweep off difficulties (women face) during pregnancy, childbirth, and kindergarten and school enrollment by all means (possible),” four central bank researchers wrote in the English-language abstract to a working paper.The 22-page document was dated March 26 and shared publicly on Wednesday.The paper stated the authors’ views do not represent that of the central bank. However, the call to drop restrictions on births marks the latest high-level discussion of how to address China’s aging population problems.Competing with India and the U.S.One of China’s main concerns is the impact these demographic changes could have on economic development.In two dedicated sections of the paper, researchers from the People’s Bank of China laid out how these demographic issues put China at an economic disadvantage to the U.S. and India.”If my country has narrowed the gap with the U.S. over the past 40 years by relying on cheap labor and the bonus of a huge population, what can it rely on in the next 30 years? This is worth thinking over,” the authors wrote in Chinese, according to a CNBC translation.They noted how the U.S. benefits from immigration even as China’s population ages. Meanwhile, India’s population and workforce will soon surpass that of China, they said.From 2019 to 2050, China’s population will decline by 2.2% while that of the U.S. will increase by 15%, the paper said, citing UN estimates.The authors added that the percentage of China’s work force is dwindling and it will lose its edge over that of the U.S. in the next few decades. In 2019, China’s workforce as a proportion of the total population was 5.4 percentage points higher than the U.S. However, by 2050, China’s workforce proportion will be 1.3 percentage points smaller than the U.S., the paper said.China’s aging populationIn a plan released in March for economic development for the next five years and beyond, Beijing said countering the effects of the aging population is one of its priorities. However, they stopped short of removing a ban on Chinese families from having more than two children.If there’s slight hesitation, (we) will miss the precious window of opportunity for birth policy to respond to the demographic transition, and repeat the mistake of developed countries.People’s Bank of China working paperEducational and technological advances are insufficient to counter the decline in population, and China should remove restrictions on births, the authors wrote.”If there’s slight hesitation, (we) will miss the precious window of opportunity for birth policy to respond to the demographic transition, and repeat the mistake of developed countries.”The paper discussed generally how China’s aging population problem is more severe than that of developed countries. In particular, the authors noted that developed countries with an aging population problem tend to be wealthier with a per capita GDP of at least $2,000, while China’s is half that at $1,000.And once the older segment of the population begins to sell property, stocks and bonds to finance their retirement, the ratio will be close to that of a labor force that is buying those assets, which could result in increased pressure on prices, the paper said.Chinese authorities are set to release results from a once-a-decade census later this month. More